Magenta Therapeutics Inc. [NASDAQ: MGTA] gained 16.56% or 1.53 points to close at $10.77 with a heavy trading volume of 1334547 shares. The company report on February 8, 2021 that Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual Meeting.
– Magenta will present a total of five abstracts, including four oral presentations, highlighting clinical and preclinical data across its portfolio –.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.
It opened the trading session at $9.38, the shares rose to $10.85 and dropped to $9.30, the range by which the price of stock traded the whole day. The daily chart for MGTA points out that the company has recorded 49.17% gains over the past six months. However, it is still -86.98% lower than its most recent low trading price.
If we look at the average trading volume of 243.10K shares, MGTA reached to a volume of 1334547 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Magenta Therapeutics Inc. [MGTA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MGTA shares is $16.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MGTA stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Magenta Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 07, 2021. The new note on the price target was released on June 08, 2020, representing the official price target for Magenta Therapeutics Inc. stock. Previously, the target price had yet another drop from $17 to $16, while Goldman kept a Neutral rating on MGTA stock.
The Average True Range (ATR) for Magenta Therapeutics Inc. is set at 0.75 The Price to Book ratio for the last quarter was 3.27, with the Price to Cash per share for the same quarter was set at 3.90.
Trading performance analysis for MGTA stock
Magenta Therapeutics Inc. [MGTA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.28. With this latest performance, MGTA shares gained by 28.83% in over the last four-week period, additionally plugging by 49.17% over the last 6 months – not to mention a drop of -23.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MGTA stock in for the last two-week period is set at 63.05, with the RSI for the last a single of trading hit 63.20, and the three-weeks RSI is set at 62.86 for Magenta Therapeutics Inc. [MGTA]. The present Moving Average for the last 50 days of trading for this stock 8.56, while it was recorded at 9.96 for the last single week of trading, and 7.96 for the last 200 days.
Magenta Therapeutics Inc. [MGTA]: A deeper dive into fundamental analysis
Return on Total Capital for MGTA is now -57.85, given the latest momentum, and Return on Invested Capital for the company is -53.53. Return on Equity for this stock declined to -53.53, with Return on Assets sitting at -48.16.
Reflecting on the efficiency of the workforce at the company, Magenta Therapeutics Inc. [MGTA] managed to generate an average of -$1,066,236 per employee.Magenta Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.70 and a Current Ratio set at 16.70.
Magenta Therapeutics Inc. [MGTA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Magenta Therapeutics Inc. posted -0.59/share EPS, while the average EPS was predicted by analysts to be reported at -0.59/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MGTA.
An analysis of insider ownership at Magenta Therapeutics Inc. [MGTA]
There are presently around $315 million, or 71.60% of MGTA stock, in the hands of institutional investors. The top three institutional holders of MGTA stocks are: TRV GP IV, LLC with ownership of 8,008,204, which is approximately 0% of the company’s market cap and around 11.79% of the total institutional ownership; GILDER GAGNON HOWE & CO LLC, holding 4,218,206 shares of the stock with an approximate value of $45.43 million in MGTA stocks shares; and CASDIN CAPITAL, LLC, currently with $36.04 million in MGTA stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Magenta Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 44 institutional holders increased their position in Magenta Therapeutics Inc. [NASDAQ:MGTA] by around 2,572,375 shares. Additionally, 32 investors decreased positions by around 1,933,257 shares, while 24 investors held positions by with 24,773,697 shares. The mentioned changes placed institutional holdings at 29,279,329 shares, according to the latest SEC report filing. MGTA stock had 8 new institutional investments in for a total of 119,950 shares, while 9 institutional investors sold positions of 107,376 shares during the same period.